Literature DB >> 10734004

A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy.

G M Halliday1, C D Hardman, N J Cordato, M A Hely, J G Morris.   

Abstract

We examined the topography and degree of cell loss within basal ganglia structures commonly involved in progressive supranuclear palsy in order to identify any relationship between degeneration in these nuclei and gaze palsy. Serial section analyses and unbiased quantitative techniques were applied to brain tissue from six cases with progressive supranuclear palsy (four with gaze palsy and two without) and six controls with no neurological or neuropathological abnormalities. The total number of nucleolated neurons within the substantia nigra pars compacta (SNc) and reticulata (SNr), the subthalamic nucleus, and the internal and external segments of the globus pallidus was determined for all subjects and the data expressed as percentages of control values to compare degeneration across these basal ganglia structures. The density of neurofibrillary tangles was also evaluated within these structures. Despite significant subcortical neurofibrillary tangle formation in all cases, there was considerable variability in the degree of neuronal cell loss in all basal ganglia regions, except the SNc which was consistently affected. There was no correlation between the ranked density of neurofibrillary tangles and the degree of neuronal cell loss in any basal ganglia region. Comparisons between cases with and without gaze palsy revealed a 40% greater decrease in the number of SNr neurons in cases with gaze palsy (75 +/- 8% loss) compared with those without (35 +/- 14% loss). This was the largest difference between these cases. As the SNr projects to the superior colliculus, degeneration of this basal ganglia structure may disrupt eye movements in progressive supranuclear palsy.

Entities:  

Mesh:

Year:  2000        PMID: 10734004     DOI: 10.1093/brain/123.4.724

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  8 in total

1.  The relationship between clinical and pathological variables in Richardson's syndrome.

Authors:  Emma C Schofield; John R Hodges; Thomas H Bak; John H Xuereb; Glenda M Halliday
Journal:  J Neurol       Date:  2011-08-12       Impact factor: 4.849

2.  Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.

Authors:  Shunsuke Koga; Naomi Kouri; Ronald L Walton; Mark T W Ebbert; Keith A Josephs; Irene Litvan; Neill Graff-Radford; J Eric Ahlskog; Ryan J Uitti; Jay A van Gerpen; Bradley F Boeve; Adam Parks; Owen A Ross; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2018-06-20       Impact factor: 17.088

Review 3.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Impaired oculomotor function in a community-based patient population with newly diagnosed idiopathic parkinsonism.

Authors:  Jan Linder; Britt-Inger Wenngren; Hans Stenlund; Lars Forsgren
Journal:  J Neurol       Date:  2011-12-16       Impact factor: 4.849

Review 5.  Voxelwise meta-analysis of white matter abnormalities in progressive supranuclear palsy.

Authors:  Jing Yang; Na Shao; Jianpeng Li; Huifang Shang
Journal:  Neurol Sci       Date:  2013-08-03       Impact factor: 3.307

6.  Basic and translational neuro-ophthalmology of visually guided saccades: disorders of velocity.

Authors:  Sushant Puri; Aasef G Shaikh
Journal:  Expert Rev Ophthalmol       Date:  2017-11-28

Review 7.  How to spot ocular abnormalities in progressive supranuclear palsy? A practical review.

Authors:  Onanong Phokaewvarangkul; Roongroj Bhidayasiri
Journal:  Transl Neurodegener       Date:  2019-07-10       Impact factor: 8.014

8.  Saccades in progressive supranuclear palsy - maladapted, irregular, curved, and slow.

Authors:  Aasef G Shaikh; Stewart A Factor; Jorge Juncos
Journal:  Mov Disord Clin Pract       Date:  2017-08-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.